Research Article
Risk Factors for COVID-19 in Patients with Hypertension
Table 3
Antihypertensive treatments of patients with COVID-19 and hypertension.
| | | All (n = 151) | Nonsevere patients (n = 106) | Severe patients (n = 45) | value |
| | Classification of etiology | | Primary | 149 (98.7) | 104 (98.1) | 45 (100) | 0.881 | | Secondary | 2 (1.3) | 2 (1.9) | 0 | |
| | Duration of hypertension, median (IQR), years | 10 (6–20) | 10 (6–13) | 15 (9–22.5) | 0.065 | | Grade | | | | | | 1 | 11 (7.3) | 10 (9.4) | 1 (2.2) | 0.175 | | 2 | 34 (22.5) | 21 (19.8) | 13 (28.9) | 0.222 | | 3 | 20 (13.2) | 15 (14.2) | 5 (11.1) | 0.614 | | Unknown | 88 (58.3) | 60 (56.6) | 28 (62.2) | 0.522 |
| | Antihypertensive therapies previously | | CCBs | 85 (56.3) | 61 (57.5) | 24 (53.3) | 0.094 | | ACEIs/ARBs | 30 (19.9) | 26 (24.5) | 4 (8.9) | 0.031 | | ACEIs | 9 (6.0) | 6 (5.7) | 3 (6.7) | 0.811 | | ARBs | 21 (13.9) | 20 (18.9) | 1 (2.2) | 0.007 | | β-Blockers | 19 (12.6) | 15 (14.2) | 4 (8.9) | 0.373 | | Anticoagulant drugs | 16 (10.6) | 13 (12.3) | 3 (6.7) | 0.238 | | Statins | 10 (6.6) | 7 (6.6) | 3 (6.7) | 0.988 | | None | 19 (12.6) | 12 (11.3) | 7 (15.6) | 0.473 | | Diuretics | 7 (4.6) | 4 (3.8) | 3 (6.7) | 0.426 | | Unknown | 14 (9.3) | 9 (8.5) | 5 (11.1) | 0.76 |
|
|
IQR: interquartile range; CCBs: calcium channel blockers; ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin II type 1 receptor blockers; anticoagulant drugs: aspirin or clopidogrel.
|
